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Morbidity and Tteatment of Clinically Important Obesity:
An Internal Medicine Perspective
J. David Fachnie, M D

Obesity is defined as an excess storage of energy in the form offal. The internist generates a
differential diagnosis of etiologic factors and examines the patient carefully. Obese persons are
counseled on all medical risks of obesity. Choices for treatment vary according lo the severity of the
obesity, and ahernalive dietary treatments include a balanced-deficit diet or a very low calorie diet.
Weight loss can be predicted by applying specified equations. With severe obesity, multidisciplinary
treatment is needed. Anorexic agenls have limiled value because of their side effecls and because of
weight increase after discontinuing therapy. Obesity is nol curable: poor patient compliance limits the
long-term efficacy of treatment. (Henry Ford Hosp MedJ 1988:36:108-12)

O

besity is defined as an excess storage of energy in the
form of fat. Physicians know that additional morbidity and
mortality is the consequence of obesity; hypertension, hypercholesterolemia, and diabetes mellitus are more common in
obese persons. Less commonly appreciated is the increased risk
of cancer in obese compared to nonobese persons; obese men
have higher mortality from colon, rectum, and prostate cancer,
and obese women have higher mortality from gallbladder, biliary passage, breast (postmenopausal), uterine (both cervix and
endometrium), and ovarian cancer (1). Obesity has a complex
etiology (somatic, psychologic, and sociocultural), and the
numerous therapies are mosfiy ineffective over the long term.
The obese patient continues to present a challenge to the clinician. In this review ofthe problem of obesity, from an internist's
point of view, the following topics will be discussed; clinically
important obesity, medical assessment, dietary treatments prescribed by physicians, risks and benefits of weight reduction induced by a very low calorie diet, and pharmacotherapy.

Clinically Important Obesity
Obesity can be described in many different ways. Clinically,
the most commonly used term is the Metropolitan Relative
Weight (MRW) scale which defines ideal weight at each height
in terms of life insurance mortality statistics. The second most
common term is the body mass index (BMI) which is defined as
body weight in kg/(height in m-). Even modest degrees of
obesity (MRW > 110%) should be noted because of the relationship to cardiovascular disease risk (2,3). The National Institutes of Health Consensus Development Conference stated
that weight reduction should be recommended for all persons
with a MRW > 120% (using the midpoint on 1983 tables for a
medium-build person) or a B M I > 27.2 for men and > 26.9 for
women (1). Risk factors for cardiovascular disease such as hy-
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pertension, personal or family history of noninsulin-dependent
diabetes mellitus (NIDDM), or dyslipidemia should prompt
intervention at lower levels of adiposity.

Medical Assessment
Two questions must be addressed in the medical evaluation of
obese persons; What are the causative factors of the obesity, and
what morbidity has the patient suffered because of obesity ? The
most prevalent causative factors are listed in Table 1. Although
there is no doubt that much obesity can be attributed .to eating behaviors that are learned, the physician should consider
physical disease as a possible cause. A detailed family history
will elucidate genetic factors (4). The onset of obesity, either
in childhood or adulthood, as well as its exacerbation during
periods of physical or psychologic stress may be helpful in
understanding the factors that have contributed to the obesity.
Hypothyroidism should be considered in all obese persons, but
its prevalence is less than 5% of those screened (5). Hypothalamic tumors, especially craniopharyngioma, may affect the
appetite center and present with obesity, headaches, and visual
disturbance (6). The Gushing syndrome is exceedingly rare and
should be excluded when the obesity is adult-onset and especially when hypertension, hyperglycemia, stria, and the like
are present. Hypogonadism may be present in obese men, and
women with polycystic ovarian disease are often obese. Persons
with the Prader Willi syndrome or the Down syndrome or mental subnormality are frequently severely obese (7).
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Table 1
DilTerential Diagnosis of Obesity
Familial
Sociocultural
Behavioral
Hypothyroidism
Mental subnormality
Hypogonadism in males
The Cushing syndrome
Hypothalamic disease
The Prader Willi syndrome
Drug-induced

The medical morbidity of obesity is legion (Table 2). A comprehensive history and physical examination should be
atiempted despite the difficulties attendant to examining some
persons who are severely obese. Assess the regularity of
menstruation and its appropriateness relative to menopausal status; disorders of androgen metabolism and ovulation are common. Examine breasts, pelvis, rectum, and prostate. Obtain
stool for occult blood. Obtain an electrocardiogram. Where indicated, obtain mammogram and proctoscopy. Obtain blood for
tests of thyroid, liver function, and fasted blood for measurement of glucose, cholesterol, triglycerides, and high-density
lipoprotein (HDL) cholesterol. Depressed HDL cholesterol (8),
fatty metamorphosis of the liver (9), and focal glomerulosclerosis (10) may be seen especially in the severely obese.
The anthropomorphic assessment of obese persons should include measurement of height, weight, waist, and hip and calculation of MRW or BMI and waist/hip ratio. The waist/hip ratio
provides supplementary information about the adverse metabolic impact of the person's obesity; adipocytes that are distributed in the gluteal-femoral region may be relafively metabolically inert, except during the latter part of pregnancy and
during lactation; adipocytes that are distributed over the abdomen are more responsive to the lipolytic effects of catecholamines. The central distribufion of adiposity brought about
by abdominal adipocytes predominating is termed android
obesity and is defined as a waist/hip rafio > 1 for men and > 0.8
for women. Android obesity is associated with cardiovascular
risk factors (hypertension, dyslipidemia, diabetes mellitus) and
is ariskfactor for ischemic heart disease, stroke, and death. Android obesity should be treated vigorously. The peripheral distribution of adiposity is seen when the waist/hip ratio is s; 1 for
men and s= 0.8 for women and is called gynecoid obesity.
Gynecoid obesity (gluteal-femoral) may not be as responsive to
treatment efforts and may not carry as adverse a prognosis (11).

Dietary IVeatments Prescribed by Physicians
The evident cause for obesity is an imbalance between energy
utilization and energy intake leading to excessive fat stores in the
adipocytes. According to Jequier (12), who reviewed the question of energy ufilizafion in human obesity, a deficient energy
utilization is not universally present in human obesity. That observation, if true, prompts the conclusion that excessive energy
intake leads to obesity. Indeed, there may be an uncoupling
between energy utilization, stimulated by exercise, and caloric
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Table 2
Medical Morbidity Associated with Obesity
Hypertension
Diabetes mellitus
Hypercholesterolemia
Depressed HDL cholesterol
Obesity hypoventilation syndrome, obstmctive sleep apnea syndrome
Osteoarthritis
Malignancy in females (breast, ovary, endometrium, cervix, gallbladder,
biliary passages)
Malignancy in males (colon, rectum, prostate)
Cholelilhia.sis
Menstrual disorders
Hirsutism
Coronary artery disease
Fatty metamorphosis of liver
Focal glomerulosclerosis

intake in obese but not in lean subjects (13). Environmental (14)
and neurochemical factors (15) may influence appetite and perhaps food choice. Most dietary treatments aim to redress the energy imbalance by restricting energy intake (caloric restriction)
and increasing energy utilization (increasing physical activity).
The present genre of medical treatments emphasize that both
dietary and physical exercise modifications must be made to attain short- and long-term success with weight reduction therapy.
While numerous popular and out-of-vogue fad diets exist,
physicians have traditionally limited dietary prescriptions to
diets that are moderate in caloric restriction yet similar to a standard diet in the amount of carbohydrate, fat, protein, and other
nutrients. These are the so-called balanced-deficit diets (BDDs).
The BDD is calculated from an esfimate of caloric expenditure,
eg, 34 to 42 kcal/kg/day in adult men and 29 to 38 kcal/kg/day in
adult women (16). By subtracting 500 kcal/day from the esfimated caloric expenditure, a weekly caloric deficit leading to
0.50 kg (1.1 lb) weight loss can be expected. A 60 kg (132 lb)
woman might be allowed as few as 1,240 kcal/day, and a 70 kg
(154 lb) man might be allowed as few as 1,880 kcal/day. Given a
protein intake of 20% of total calories, the recommended daily
allowance of 0.8 g/kg/day would easily be met. The risk from
these diets is minimal for all persons except the insulin-taking
diabetic with close to normal blood glucose control; such persons must have downward adjustment of their insulin dose and
close monitoring of blood glucose when caloric-restricted dieting begins.
Given a diet prescription, what will be the predicted weight
loss in a compliant person? James (17) described equations to
estimate the daily energy (E) requirements of very sedentary,
mild and moderately obese persons (Table 3). Because ofthe reduced basal metabolic rate with dieting, the factor 1.4 should be
reduced to 1.25 in all equations after one month on the diet.
Once E has been calculated, the difference between E and the
energy intake (I) in kcal/day will yield the daily energy gap (G).
A deficit of 7,200 kcal is associated with a 1 kg (2.2 lb) loss of
weight; hence, predicted weight loss can be estimated. Variations in energy expenditure among the obese are not very great
(18); therefore, failure to achieve close to the predicted weight
loss suggests that dietary indiscretion is at fault.
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Table 3
Predicting Weight Loss From a Diet*
1. EsUmating daily energy (E) requirements (kcal/day):
18 to 30 years:
Men
E = 1.4(0.063 x weightt -I- 2.9) x 240
Women E = 1.4(0.062 X weight -I- 2.0) x 240

Table 4
Indications and Contraindications to the
Very Low Calorie Diet
Indications
> 30% over MRW*
Morbidity due to obesity

30 to 60 years:
Men
E = 1.4(0.048 x weight -I- 3.65) x 240
Women E = 1.4(0.034 X weight -I- 3.5) x 240
2. Specify daily dietary intake (I)
3. Daily energy gap (G): G = E — I
4. Convert kg weight loss: 7.200 kcal deficit leads to 1 kg weighl loss
*From James WPT (Treatment of obesity: The constraints on success. Clin Endocrinol
Metab 1984; 13:646-7). See text for further explanation,
rkg body weight.

The most popular medical therapy for severe obesity is the
very low calorie diet (VLCD) which is also called the proteinsparing modified fast. The VLCD is intended to promote rapid
weight loss by reducing calories: between 400 and 800 kcal/day
are prescribed. The dangerous loss of lean body mass from total
fasting is avoided by the provision of ample amounts of protein
(> 1 g/kg of ideal body weight daily) that has high biologic value
(meat, egg albumin, casein) (19). The carbohydrate and fat components of the VLCD are severely restricted, but the recommended daily allowance of other nutrients is given. Because of
the extreme nature of the.se diets, physician selection of suitable
candidates and careful medical monitoring, usually weekly, are
required to ensure the safety of the patient. The decision to prescribe a VLCD must include an assessment of the patient's ability to comply strictly to an unusual dietary regimen. Frequently,
a BDD is given for one or two weeks prior to the VLCD; this trial
of a BDD allows for evaluation of the patient's motivation and
ability to comply with a dietary prescription. An informed consent form should be read and signed by the patient to ensure that
he or she understands the dietary regimen and its possible complications. The VLCD is expensive for both patient and insurer
and taxes available health professional manpower because of the
need for weekly contact with the patient who is on a VLCD. A
list of the most common indications for and contraindications to
the VLCD is given in Table 4. The contraindications include
conditions that may be aggravated by the diet (unstable cardiac,
renal, or hepatic disease, active peptic ulcer, untreated neuropsychiatric illness, or healing after major surgery). Adequate
data pertaining to the effects on developing humans, including
human fetuses, are not available. Persons over age 65 occasionally may be given a VLCD, but they may be at greater risk for
complications, particularly vascular complications, if they have
significant atherosclerosis. Active alcoholics cannot comply
with the behavioral strictures of the VLCD.

Risks and Beneflts of Weight Reduction Induced
by a VLCD
In the late 1970s, many deaths were reportedly associated
with hypocaloric dieting. In most reported cases, hydrolyzed
collagen, a substance with low biologic value, was the main protein source of the diet (20). The cause of death was cardiac; myocardial atrophy was seen pathologically. Curiously, the deaths
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Contraindicarions
During growth and developmentt
Pregnancy or risk of pregnancy
Age over 65 yearst
Recent cardiovascular or cerebrovascular event
Recent major surgery
Major organ failure (cardiac, renal, hepatic)
Un.stable angina pectoris
Active peptic ulcer di.sea.se
Untreated psychosis or depressive illness
Active alcoholism
*Metropolitan Relative Weight. See text for delinition.
tOccasionally a very low calorie diet may be justified.

occurred earlier in the less obese than in the more obese persons,
which suggested that persons with more severe obesity were relatively protected from loss of lean body mass when compared to
those who were less obese (21). The present generation of
VLCDs uses high biologic value protein and has been shown to
produce protein sparing by decreasing body protein mobilization and increasing reutilization of body protein. The present
genre of VLCDs are relatively safe when compared to the hydrolyzed collagen diets. In a comprehensive review of the VLCD.
Fisler and Drenick (19) described variable loss of protein or fat
over time with VLCD ingestion; during the first two weeks on a
VLCD, the protein loss is 6% to 10% and fat loss is 30% to 50%;
by the fourth week a stable pattem emerges with protein loss of
5% to 10% and fat loss of 70%. The early loss of lean body mass
is largely the consequence of diuresis, but a negative nitrogen
balance has also been frequently observed. Other losses include
potassium, sodium, magnesium, phosphate, zinc, copper, calcium, and B vitamins. Balance studies have shown that with
supplementation a positive balance in sodium, magnesium, copper, and B vitamins can be obtained (19). Meticulous attention
must be paid to vitamin and mineral replacement during very
low calorie dieting.
Within days of starting the VLCD, a brisk diuresis and
natriuresis ensues. Therefore, diuretic therapy must be used with
caution. Orthostatic hypotension may be seen in some f)ersons, especially those who fail to maintain adequate fluid and electrolyte
intake. Hyperuricemia and precipitation of acute gouty arthritis
may occur, although rarely. Persons on insulin or oral hypoglycemic agents must be monitored carefully with appropriate
reduction of medication as indicated by frequent blood gluco,se
measurements. Transient elevation of SGOT or SGPT is usually
followed, within months, by normalization of the aberrant values
(10). Cholesterol and triglyceride decrease during the VLCD; this
reduction supports the impression that the patient is complying with
the diet (8). Values for sodium, potassium, creatinine, albumin,
calcium, and glucose remain normal in most instances but should
be monitored along with liver function tests at least every four

Morbidity and Treatment of Obesity—Fachnie

weeks. The dangerous cardiac arrhythmias and myocardial atrophy
associated with the hydrolyzed collagen fasts are not seen in the
presently used VLCD (22). However, an electt-ocardiogram should
be obtained periodically; pay particular attention to rhythm and the
QT interval (23).
Obese women who experience irregular menstrual cycles
have elevated levels of blood androgens whether or not hirsutism
is present (24). Weight reduction may ameliorate the hyperandrogenemic state. One consequence of weight loss is the resumption of ovulatory menstrual cycles; two pafients in our
clinic conceived unexpectedly while on the VLCD. Because the
VLCD may be unsafe for use during pregnancy, we urge the use
of effective birth control methods and wam against pregnancy in
all reproductive-age women on the VLCD, regardless ofthe history of fecundity.
The three major morbidities of obesity (hypertension, hypercholesterolemia, and diabetes mellitus) are improved by weight
reduction. The relafionship of obesity and hypertension is discussed in an excellent review article in this Joumal (25). The
dyslipidemia of obesity is characterized by elevation of cholesterol and depression of HDL cholesterol. During the period of
weight loss induced by a VLCD, the total cholesterol and triglycerides fall; after the V1X:D is completed, when the person is
maintaining a stable, lower weight, the HDL cholesterol is
higher and the cholesterol/HDL cholesterol ratio is lower than
before the diet—a favorable change from the standpoint of cardiovascular risk (8,26,27). Persons who are genetically at risk
for NIDDM will carry a greater risk for becoming overtiy hyperglycemic if factors that increase the target cell resistance to
insulin action are present. Obesity is associated with hyperinsulinemia and resistance to the acfion of insulin; the binding
of insulin to target cells is diminished (28,29). The VLCD will
reduce blood glucose and hyperinsulinemia in obese persons
with NIDDM (30,31). Despite weight reducfion, defects in the
first phase of insulin release by the pancreas may not reverse
(32).
The safety of the VLCD depends on careful prescribing of a
high biologic value, nutritionally complete supplement to carefully selected, compliant persons. Few deaths have been attributed to the present genre of VLCDs. The efficacy of the
VLCD is excellent in terms of its ability to induce rapid weight
loss with safety, typically 1 to 2 kg/week (22). A recent study of
weight loss in a combined VLCD and behavior therapy program
has reported that poor patient compliance adversely affects
long-term maintenance of weight loss (33). Adverse behaviors
include I) premature withdrawal from the VLCD prior to achieving goal weight, and 2) failure to enroll in a weight maintenance
program after the VLCD to help sustain weight loss.

Pharmacotherapy
Current therapy for obesity emphasizes behavioral modification to change adverse eating behaviors, reducfion of caloric intake, and rarely surgical treatment. Anorexic agents have fallen
into disfavor because of side effects, abuse potential, and uncertain long-term efficacy. Douglas and Munro (34) recommend
antiobesity drugs if dietary treatment has failed after four to
eight weeks. Galloway et al (35) state that weight regain after
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discontinuafion of antiobeshy drugs limits their indications to
short-term goals such as presurgery weight reduction. Stunkard
et al (36) obtained evidence that fenfluramine treatment resulted
in more long-term weight regain than behavior therapy alone.
The possibility that combinafions of available anorexics may
achieve similar degrees of weight loss with fewer side effects is
promising (37). The declining clinical use of available anorexics
will not reverse until their cost/benefit ratio is shown to be more
favorable. The atomistic approach to developing new antiobesity drugs is well summarized by Sullivan et al (38).

Final Comment
Each obese person should be counseled about the known
medical risks of obesity. This counseling is best done in a supportive and nonjudgmental way. Referral for obesity treatment
should be appropriate to the pafient's risk from the disorder; for
milder obesity, give dietary advice; for severe obesity, refer to a
well-run multidisciplinary obesity treatment program. Curafive
treatments for obesity are not on the horizon. The benefits of
treatment cannot be assessed solely by the rate of recidivism
after a specified period oftime.Periodic weight loss may be beneficial to obese persons even if substantial relapse of obesity
subsequently occurs (8). Obese persons who are regaining
weight lost must be encouraged to retum promptly to the obesity
treatment program. Patients who attend maintenance programs
that incorporate exercise and diet modification will be more
likely to sustain weight loss.
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